ABL1 and acute lymphoblastic leukemia: Using the BCR-ABL1 fusion as a marker for MRD in Ph-positive B-ALL patients is more efficient and less labour-intensive than is RQ-PCR detection of Ig/TCR gene rearrangements, which requires patient-specific probes.